Board of Directors

 

Pankaj Mohan, Ph.D.

Chairman, CEO & President


Dr. Mohan has served as our President, Chief Executive Officer and as Chairman and a member of our board of directors since January 2011. Prior to founding our company, from May 2008 to December 2010, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company. From June 2006 to May 2008, Dr. Mohan served as a Director of Bioprocess Engineering at Genentech, Inc., a biotechnology company. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom. From August 1987 to December 1989, Dr. Mohan served as a Scientific Officer for the Department of Atomic Energy for the Government of India.

Dr. Mohan has served as Chairman and as a member of the board of directors of Sonnet Biotherapeutics, Inc. since its inception in April 2015.

Dr. Mohan received a Ph.D. in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a masters in Financial Management from Middlesex University Business School, London, United Kingdom, an Executive Management Program (AMP) from Fuqua School of Business at Duke University and a Bachelor of Chemical Engineering from the Indian Institute of Technology in Roorkee, India.

 

Todd C. Brady, M.D., Ph.D.

Dr. Brady has served as a member of our board of directors since September 2014. Since January 2012, Dr. Brady also has served as Chief Executive Officer and President of Aldeyra Therapeutics, Inc., a biotechnology company, and has served as a member of its board of directors since September 2005. Dr. Brady also serves as a member of the board of directors of Evoke Pharma, Inc., Novadigm Therapeutics, Inc. and Cantex Pharmaceuticals, Inc. From 2004 to 2013, Dr. Brady served as an entrepreneur-in-residence and principal at Domain Associates, a healthcare venture capital firm.

Dr. Brady received an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School and an A.B. from Dartmouth College.

 

Scott Canute

Mr. Canute has served as a member of our board of directors since October 2011. From March 2010 to July 2011, Mr. Canute served as the President of Global Manufacturing and Corporate Operations of Genzyme Corporation. Prior to that, from 1982 to 2007, Mr. Canute served in various management positions at Eli Lilly and Company, including as the President of Global Manufacturing Operations, Vice President of Global Manufacturing, Vice President of Global Pharmaceutical Manufacturing and General Manager of European Manufacturing Operations. Mr. Canute also serves as a member of the technical advisory board of Moderna Therapeutics, Inc., and as a member of the board of directors of Proteon Therapeutics, Inc. and Flexion Therapeutics, Inc. In addition, Mr. Canute formerly served as a member of the board of directors of Inspiration Biopharmaceuticals, Inc. and AlloCure Inc.

Mr. Canute received an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Michigan.

 

Albert D. Dyrness

Mr. Dyrness has served as a member of our board of directors since December 2015.  He has more than 20 years of experience in the design, start-up and qualification of systems and equipment used in the manufacture of biologics and pharmaceuticals. He is a recognized industry leader in bio-process engineering with expertise in upstream, downstream, and fill/finish processes. In 1988, he co-founded ADVENT Engineering Services, a privately-held engineering services firm that serves the energy and life sciences industries, and currently heads its Life Sciences Division. Mr. Dyrness currently serves as the Vice-Chairperson for the American Society of Mechanical Engineers Bioprocess Equipment Standard (AMSE-BPE) System Design subcommittee. He is an Industrial Advisory Board Member of the University of the Pacific’s Bioengineering Program.

Mr. Dyrness holds an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and professional engineer licenses in the state of California for both Chemical and Mechanical Engineering.
 

 

 

Donald J. Griffith, C.P.A.

Mr. Griffith has served as a member of our board of directors since August 2011 Mr. Griffith served as our Chief Financial Officer and Secretary from May 2011 through September 2015. Mr. Griffith currently serves as President, Chief Executive Officer and Treasurer of Sonnet Biotherapeutics, Inc. and also serves as a member of its board of directors. From May 1991 to May 2011, Mr. Griffith served as a partner at Stolz & Griffith, LLC, a New Jersey accounting firm.

Mr. Griffith is an active member of the New Jersey Society of CPAs and the American Institute of CPAs. Mr. Griffith received an M.B.A. from Fairleigh Dickenson University and a B.B.A. in Business Administration from the City College of New York.

 

Kurt J. Hilzinger

Mr. Hilzinger has served as a member of our board of directors since December 2015. He has extensive experience with companies that manage the supply of pharmaceuticals. He spent 16 years in various executive management capacities with AmerisourceBergen Corporation, serving as president and chief operating officer and earlier as executive vice president and chief financial officer. In 2007, he became a partner at Court Square Capital Partners, a private equity firm. Since 2003, Mr. Hilzinger has been on the board of managed care company, Humana, including serving as lead director from 2010 to 2014 when he became chairman of the Board. He serves on the Visiting Committee at the Ross School of Business at the University of Michigan, and also formerly served as Chairman of the Healthcare Distribution Management Association (HDMA), the trade association of the pharmaceutical distribution industry.

Mr. Hilzinger received his B.B.A. degree from the University of Michigan and is a Certified Public Accountant.
 

Robin Smith Hoke

Ms. Hoke has served as a member of our board of directors since December 2015.  She is a seasoned business and legal executive with over 20 years of healthcare and pharmaceutical experience in various legal and business roles where she focused on strategy, business development, acquisitions, and strategic relationships, including, strategic alliances, joint ventures, partnerships and other investments. Ms. Hoke currently provides pharmaceutical and healthcare advisory services to multi-national, mid-tier and emerging companies and private equity firms. She served as chair of the Board of Directors and interim chief executive officer at Ricerca Biosciences, LLC. Prior to Ricerca, Ms. Hoke served as the president of GeneraMedix, Inc., and held senior legal and business roles at Cardinal Health, Inc. She also spent time with Abbott Laboratories, Inc., and served as a partner in the business law firm of Kegler, Brown, Hill & Ritter, Co., L.P.A.

Ms. Hoke received her B.S. from Michigan State University and her law degree from Thomas M. Cooley Law School.
 

 


 

Board Observers and Advisors:

 

Balu N. Balasubramanian, Ph.D.
Advisor

Dr. Balasubramanian currently leads the Pharma Innovation Sourcing Center. He is a former executive from Bristol-Myers Squibb (most recently Managing Director of the BMS-Biocon R&D Center) with over 25 years of scientific and management experience in drug discovery and early clinical development.

 

Arun Kumar
Observer

Mr. Kumar is the Founder and Promoter Director of Strides ArcoLab Limited, a pharmaceutical company headquartered in Bangalore, India. He has been a member its Board as Managing Director since its inception in 1990. Mr. Kumar was previously General Manager of British Pharmaceuticals Limited.

 

Nailesh Bhatt
Advisor, Commercialization

Mr. Bhatt is the Managing Director of Proximare and is assisting Oncobiologics in development of a US sales and marketing strategy which includes the identification and interactions between (i) payors, (ii) providers, (iii) pharmacy benefit management organizations, (iv) patients and (v) physicians.